Brief: YS Biopharma Announces Interim Results Of Late-Stage Clinical Study Of PIKA Rabies Vaccine
09/04/2024 13:51
April 9 (Reuters) - YS Biopharma Co Ltd H6Z.F :
* YS BIOPHARMA ANNOUNCES POSITIVE INTERIM RESULTS OF PIVOTAL
PHASE
3 CLINICAL STUDY OF PIKA RABIES VACCINE
* YS BIOPHARMA CO LTD: PIKA RABIES VACCINE HAS SUCCESSFULLY
MET
PRIMARY ENDPOINTS OF TRIAL
* YS BIOPHARMA: PIKA RABIES VACCINE DEMONSTRATES
NON-INFERIOR
IMMUNOGENICITY TO GLOBALLY MARKETED COMPARATOR
Source text for Eikon: ID:nPn6YK6LKa
Further company coverage: H6Z.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LakeShore Biopharma Co
See all newsBrief: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
Brief: LakeShore Biopharma Appoints Advisors to Special Committee Reviewing Takeover Bid
Brief: Lakeshore Biopharma Announces Receipt Of A Preliminary Non-Binding Proposal To Acquire The Company
Brief: Lakeshore Biopharma Expects 2026 Revenue To Be Between RMB550 Million And RMB650 Million
Brief: Lakeshore Biopharma Announces Us$15 Million Private Placement Financing